Roche

News

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.

News

Roche's AI-powered digital pathology open environment in action

Roche accelerates AI adoption with NVIDIA deal

Roche has ramped up its investment in NVIDIA's AI chips, launching a hybrid-cloud AI factory that it believes is the largest in the pharma industry.

News

Roche's oral SERD flunks phase 3 breast cancer test

Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.

News

Zealand hit as Roche-partnered obesity drug disappoints

Shares in Zealand lost a third of their value today, after the biotech reported phase 2 data with Roche-partnered weight-loss therapy petrelintide.

News

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?

News

Mark Dawson named head of Roche's pRED unit

Roche has appointed leading Australian cancer researcher Mark Dawson to lead its pRED R&D division, as the company prepares for a steep patent cliff.

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Roche accelerates AI adoption with NVIDIA deal

Roche's oral SERD flunks phase 3 breast cancer test

Zealand hit as Roche-partnered obesity drug disappoints

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Mark Dawson named head of Roche's pRED unit

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

Roche

Editor's Picks